BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 23.42 USD 0.77% Market Closed
Market Cap: 4.4B USD
Have any thoughts about
BridgeBio Pharma Inc?
Write Note

BridgeBio Pharma Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BridgeBio Pharma Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
BridgeBio Pharma Inc
NASDAQ:BBIO
Net Income (Common)
-$438.9m
CAGR 3-Years
6%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

BridgeBio Pharma Inc
Glance View

Market Cap
4.4B USD
Industry
Biotechnology

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 576 full-time employees. The company went IPO on 2019-06-27. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561, BBP-711, BBP-631 and BBP-454.

BBIO Intrinsic Value
30.56 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is BridgeBio Pharma Inc's Net Income (Common)?
Net Income (Common)
-438.9m USD

Based on the financial report for Sep 30, 2024, BridgeBio Pharma Inc's Net Income (Common) amounts to -438.9m USD.

What is BridgeBio Pharma Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-14%

Over the last year, the Net Income (Common) growth was 28%. The average annual Net Income (Common) growth rates for BridgeBio Pharma Inc have been 6% over the past three years , -14% over the past five years .

Back to Top